Table 2. Overview of immunotherapy of EGFR ex20ins-mutant NSCLC.
| Study | Treatment | Year | Number of patients | ORR (%) | mPFS (months) | mOS (months) |
|---|---|---|---|---|---|---|
| Metro et al. (39) | ICB monotherapy | 2021 | 12 | 6.7 | 2 | 5.3 |
| Christopoulos et al. (40) | Chemotherapy + ICB | 2022 | 25 | 24 | 6.5 | NR |
| Yang et al. (41) | Chemotherapy + ICB | 2023 | 15 | 40 | 6.53 | NR |
| Trummer et al. (42) | Chemotherapy + atezolizumab + bevacizumab | 2022 | 9 | 88.9 | 13.6 | NR |
| Ou et al. (43) | 1L ICB monotherapy | 2021 | 11 | 9.1 | 3.1 | 11 |
| 1L ICB + platinum | 2021 | 16 | 18.8 | 4.5 | 11.3 | |
| ≥2L ICB monotherapy | 2021 | 32 | 3.1 | 2.3 | 8.1 | |
| Lau et al. (44) | Immunotherapy monotherapy | 2021 | 6 | 50 | 4.8 | NR |
| Gao et al. (38) | Camrelizumab + apatinib | 2022 | 3 | 33.3 | 8.3 | NR |
| Morita et al. (45) | ICBs | 2021 | 8 | 25 | 3.1 | NR |
EGFR, epidermal growth factor receptor; ex20ins, exon 20 insertion; NSCLC, non-small cell lung cancer; ORR, overall response rate; mPFS, median progression-free survival; mOS, median overall survival; ICB, immune checkpoint blockade; NR, not reported; 1L, first-line; 2L, second-line.